drugset / Trial / NCT07435129
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
RandomizedParallel-groupTriple-blindTreatment
Summary
A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD
Timeline
- Start
- 2026-08
- Primary completion
- 2028-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apitegromab | Monoclonal antibody | 10 mg/kg | Intravenous |